We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$713M
Cap. Flow
+$1.03B
Cap. Flow %
77.19%
Top 10 Hldgs %
46.07%
Holding
196
New
82
Increased
39
Reduced
17
Closed
45

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$20M
2
XLRN
Acceleron Pharma
XLRN
+$18.6M
3
TARA icon
Protara Therapeutics
TARA
+$12.9M
4
BTAI icon
BioXcel Therapeutics
BTAI
+$12M
5
VSTM icon
Verastem
VSTM
+$11M

Top Sells

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$5.72M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.63M
3
TGTX icon
TG Therapeutics
TGTX
+$3.51M
4
KALA icon
KALA BIO
KALA
+$3.39M
5
ARQL
Arqule Inc
ARQL
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 19.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
151
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$46K ﹤0.01%
3,184
– –
AGIO icon
152
CALL
Agios Pharmaceuticals
AGIO
$1.79B
– –
-50,000
Closed -$2.39M
ANAB icon
153
AnaptysBio
ANAB
$1.58B
– –
-143,000
Closed -$2.32M
ANAB icon
154
PUT
AnaptysBio
ANAB
$1.58B
– –
-193,300
Closed -$3.14M
APLS
155
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-240,300
Closed -$7.36M
APLS
156
PUT
DELISTED
Apellis Pharmaceuticals
APLS
– –
-286,900
Closed -$8.79M
ARVN icon
157
PUT
Arvinas
ARVN
$518M
– –
-3,100
Closed -$127K
ARWR icon
158
CALL
Arrowhead Research
ARWR
$11.9B
– –
-100,000
Closed -$6.34M
ASND icon
159
CALL
Ascendis Pharma A/S
ASND
$16B
– –
-69,400
Closed -$9.65M
DNTH icon
160
Dianthus Therapeutics
DNTH
$5.84B
– –
-542
Closed -$131K
DTIL icon
161
Precision BioSciences
DTIL
$180M
– –
-2,667
Closed -$1.11M
GOSS icon
162
PUT
Gossamer Bio
GOSS
$82.9M
– –
-771,100
Closed -$12.1M
IBB icon
163
PUT
iShares Biotechnology ETF
IBB
$9.34B
– –
-250,000
Closed -$30.1M
INCY icon
164
CALL
Incyte
INCY
$24.2B
– –
-80,000
Closed -$6.99M
KALA icon
165
CALL
KALA BIO
KALA
$14.1M
– –
-158
Closed -$1.46M
MDGL icon
166
PUT
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-100,000
Closed -$9.11M
MGNX icon
167
CALL
MacroGenics
MGNX
$235M
– –
-150,000
Closed -$1.63M
NVAX icon
168
Novavax
NVAX
$1.2B
– –
-25,049
Closed -$100K
OCUL icon
169
CALL
Ocular Therapeutix
OCUL
$1.79B
– –
-150,000
Closed -$593K
PBYI icon
170
CALL
Puma Biotechnology
PBYI
$404M
– –
-132,700
Closed -$1.16M
PRTA icon
171
Prothena Corp
PRTA
$425M
– –
-29,832
Closed -$472K
TGTX icon
172
TG Therapeutics
TGTX
$7.96B
– –
-316,200
Closed -$3.51M
VKTX icon
173
CALL
Viking Therapeutics
VKTX
$3.7B
– –
-150,000
Closed -$1.2M
VKTX icon
174
PUT
Viking Therapeutics
VKTX
$3.7B
– –
-150,000
Closed -$1.2M
WVE icon
175
CALL
Wave Life Sciences
WVE
$1.09B
– –
-134,400
Closed -$1.08M
4 5 6
7
8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Ikarian Capital held 196 positions worth $1.33B, up 115% from $617M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ikarian Capital deployed $1.03B of net new capital in Q1 2020, opening 82 new positions and adding to 39 existing holdings. Its largest new stake was Zogenix, Inc.: 549,459 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 16% a quarter earlier.

On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $4.63M trimmed.

  • Ikarian Capital's largest Q1 2020 buy was Zogenix, Inc.: 549,459 shares worth $13.6M.
  • Ikarian Capital added most to Protara Therapeutics in Q1 2020, an estimated $12.9M increase.
  • Ikarian Capital's biggest Q1 2020 reduction was Aurinia Pharmaceuticals, cutting an estimated $4.63M.
  • Ikarian Capital fully exited Aptose Biosciences, Inc. in Q1 2020, selling an estimated $5.72M.
  • Ikarian Capital's ten largest holdings make up 46% of its $1.33B portfolio in Q1 2020.
  • Ikarian Capital opened 82 new positions and closed 45 in Q1 2020.
  • Ikarian Capital's portfolio value rose 115% quarter-over-quarter to $1.33B.

Based on Ikarian Capital's 13F filing for Q1 2020, filed 15 May 2020.